Elizabeth M. Hawkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Elizabeth M. Hawkins has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alice Bass
1 shared publicationBenjamin A. Blizard
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication- Benjamin Louis Moresco
Department of Pediatrics, Division of Pediatric Palliative Care (M.E.H., B.L.M., C.D.C.), University of Utah, Salt Lake City, Utah
1 shared publication - Bridget McKay
Mammoth Biosciences, Inc. Brisbane California USA
1 shared publication - Carley G. Hendriks
Mammoth Biosciences, Inc., 1000 Marina Blvd, Suite 600, Brisbane, CA 94005, USA
1 shared publication Danielle Jonas
1 shared publication
Latest Publications
- 11 April 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 63 (5) , 794
State of the Science in Pediatric Palliative Care (TH143)
- 11 April 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 63 (5) , 794
State of the Science in Pediatric Palliative Care (TH143)
- Open Access
- 10 September 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (7) , 2100304
CRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
The programmable nature of sequence‐specific targeting by CRISPR‐Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross‐disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID‐19 pandemic. We further discuss the advances and potential for CRISPR‐based detection to have an impact across a continuum of diagnostic applications.
- 10 September 2021
- Published by Wiley in Biotechnology Journal
- Vol. 17 (7) , 2100304
Open AccessCRISPR‐Cas enzymes: The toolkit revolutionizing diagnostics
The programmable nature of sequence‐specific targeting by CRISPR‐Cas nucleases has revolutionized a wide range of genomic applications and is now emerging as a method for nucleic acid detection. We explore how the diversity of CRISPR systems and their fundamental mechanisms have given rise to a wave of new methods for target recognition and readout. These cross‐disciplinary advances found at the intersection of CRISPR biology and engineering have led to the ability to rapidly generate solutions for emerging global challenges like the COVID‐19 pandemic. We further discuss the advances and potential for CRISPR‐based detection to have an impact across a continuum of diagnostic applications.